Response of Early Stage B-CLL to Interferon-α:2 Years Experience of a Pilot Study
Chronic lymphocytic leukemia of B cell-type (B-CLL) is looked upon as the most common form of leukemia in the western hemisphere. The prognosis varies from 6 months to 25 years. Cytoreductive therapy is usually restricted to patients with hemopoietic insufficiency or with progressive lymphomas. A major problem in these patients, however, is the complex immunodeficiency involving both humoral and cell-mediated immune responses. Cytotoxic regimen have to be used cautiously in order to avoid further deterioration of the immune defense . Therefore, treatment with interferon (IFN) might be an alternative therapeutic strategy, acting in an antineoplastic way and stimulating the immune system at the same time.
KeywordsDepression Lymphoma Leukemia Oncol Interferon
Unable to display preview. Download preview PDF.
- 7.O’Connell MJ, Colgan JP, Oken MM, Ritts RE, Kay ME, Itri LM (1986) Clinical trial of recombinant leukocyte A interferon as initial therapy for favourable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukemia:an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 4:128–136PubMedGoogle Scholar
- 11.French Cooperative Group on Chronic Lymphocytic Leukemia (1986) Effectiveness of “CHOP” regimen in advanced untreated chronic lymphocytic leukemia. Lancet 1:1346–1349Google Scholar
- 12.Thiel E, Schlag R, Hill W, Kettner G, Flieger D, Ziegler HWL (1987) B-Cll in early phase responds to recombinant alpha-2b interferon therapy as determined in a pilot study (abstract). Blut 55:243Google Scholar
- 15.International Workshop on Chronic Lymphocytic Leukemia (1989) Chronic lymphocytic leukemia:recommendations for diagnosis, staging, and response criteria. Ann Int Med 110:236–238Google Scholar
- 26.Kempin S, Lee BJ, Thaler HT, Koziner B, Hecht S, Gee T, Arlin Z, Little C, Straus D, Reich L, Philips E, Al-Mondhiry H, Dowling M, Mayer K, Clarkson B (1982) Combination chemotherapy of advanced chronic lymphocytic leukemia:the M–2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood 60:1110PubMedGoogle Scholar